MCID: THY023
MIFTS: 65

Thymoma

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thymoma

MalaCards integrated aliases for Thymoma:

Name: Thymoma 11 58 75 53 5 43 14 16 71
Primary Thymic Epithelial Neoplasm 58
Primary Thymic Epithelial Tumor 58
Thymus Neoplasms 71

Characteristics:


Prevelance:

1-9/1000000 (Europe) 1-9/100000 (Europe) 58

Age Of Onset:

Adult 58

Age Of Death:

normal life expectancy 58

Classifications:



Summaries for Thymoma

Disease Ontology: 11 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary: Thymoma, also known as primary thymic epithelial neoplasm, is related to thymic carcinoma and cortical thymoma. An important gene associated with Thymoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and Class I MHC mediated antigen processing and presentation. The drugs Pembrolizumab and Tubulin Modulators have been mentioned in the context of this disorder. Affiliated tissues include thymus, lung and thyroid, and related phenotypes are chest pain and weight loss

Orphanet: 58 Thymoma is a thymic epithelial neoplasm (TEN; see this term), a rare malignancy that arises from the epithelium of the thymic gland.

Wikipedia: 75 A thymoma is a tumor originating from the epithelial cells of the thymus that is considered a rare... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 953)
# Related Disease Score Top Affiliating Genes
1 thymic carcinoma 32.6 NKX2-1 KIT GTF2I DNTT CD5
2 cortical thymoma 32.6 TTN AIRE
3 epithelial malignant thymoma 32.5 TTN CD5 AIRE
4 myasthenia gravis 32.5 TTN RYR1 IL2 CTLA4 AIRE
5 encapsulated thymoma 32.3 DNTT CD5
6 dendritic cell thymoma 32.2 TTN DNTT CD5 AIRE
7 mediastinal cancer 31.6 NKX2-1 KIT CD5
8 autoimmune disease 31.2 TTN LCK IL2 CTLA4 CD5 AIRE
9 myocarditis 31.1 TTN PTPRC IL2 CTLA4 AKT1
10 thymus cancer 31.1 TTN PTPRC NKX2-1 LCK KIT IL2
11 thyroiditis 31.0 IL2 CTLA4 AIRE
12 respiratory failure 31.0 TTN RYR1 NKX2-1 IL2
13 pemphigus 31.0 PPL EVPL CTLA4
14 anemia, autoimmune hemolytic 30.9 IL2 CTLA4 CD5
15 immune deficiency disease 30.8 PTPRC LCK IL2 CTLA4 CD5 AKT1
16 t cell deficiency 30.7 PTPRC IL2 CTLA4
17 thymus lipoma 30.7 GTF2I DNTT
18 common variable immunodeficiency 30.7 LCK IL2 CTLA4 AKT1
19 ectopic thymus 30.6 NKX2-1 CD5
20 small cell cancer of the lung 30.6 PTPRC NKX2-1 KIT AKT1
21 vitiligo-associated multiple autoimmune disease susceptibility 1 30.5 IL2 CTLA4 AIRE
22 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 30.5 AKT3 AKT2 AKT1
23 pemphigoid 30.5 PPL IL2 EVPL
24 alopecia areata 30.5 IL2 CTLA4 AIRE
25 combined immunodeficiency 30.5 PTPRC LCK IL2 CTLA4 AKT1 AIRE
26 t-cell acute lymphoblastic leukemia 30.4 PTPRC LCK IL2 CD5 AKT1
27 neuroendocrine carcinoma 30.3 PTPRC NKX2-1 KIT
28 neuromuscular junction disease 30.3 TTN RYR1 DPYSL5
29 mast cell neoplasm 30.2 KIT IL2 CTLA4
30 lymphoma, non-hodgkin, familial 30.2 PTPRC LCK IL2 DNTT CTLA4 CD5
31 squamous cell carcinoma 30.0 NKX2-1 HRAS AKT3 AKT2 AKT1
32 testicular germ cell tumor 30.0 LRRC56 KIT HRAS
33 thymus adenocarcinoma 30.0 KIT CD5
34 thymus clear cell carcinoma 30.0 NKX2-1 KIT CD5
35 skin disease 30.0 PTPRC KIT IL2 HRAS CTLA4 AKT1
36 exanthem 29.9 KIT IL2 HRAS CTLA4 AKT1
37 acute biphenotypic leukemia 29.9 KIT DNTT CD5
38 b-lymphoblastic leukemia/lymphoma 29.8 PTPRC KIT DNTT
39 thyroid tumor 29.8 LRRC56 HRAS AKT1
40 iga pemphigus 29.8 PPL EVPL
41 skin carcinoma 29.7 KIT HRAS CTLA4 AKT3 AKT1
42 hairy cell leukemia 29.7 PTPRC IL2 CD5
43 peripheral nervous system disease 29.7 TTN RYR1 PTPRC KIT IL2 HRAS
44 connective tissue disease 29.7 PTPRC IL2 KIT HRAS CTLA4 AKT1
45 thyroid gland follicular carcinoma 29.7 NKX2-1 HRAS AKT1
46 sezary's disease 29.6 IL2 CTLA4 CD5
47 leukemia, acute lymphoblastic 29.5 PTPRC KIT IL2 HRAS DNTT CTLA4
48 cowden syndrome 1 29.5 HRAS AKT3 AKT2 AKT1
49 lung cancer susceptibility 3 29.4 NKX2-1 LRRC56 HRAS AKT2 AKT1
50 myeloma, multiple 29.4 PTPRC NKX2-1 LRRC56 IL2 HRAS AKT1

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

58 30 (show all 39)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chest pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0100749
2 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
3 abnormal lymphocyte proliferation 58 30 Frequent (33%) Frequent (79-30%)
HP:0031378
4 muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001324
5 fever 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001945
6 immunodeficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002721
7 dyspnea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002094
8 cough 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012735
9 hoarse voice 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001609
10 abnormality of the mediastinum 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0045026
11 night sweats 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030166
12 decreased circulating antibody level 30 Occasional (7.5%) HP:0004313
13 anti-acetylcholine receptor antibody positivity 30 Occasional (7.5%) HP:0030208
14 myalgia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0003326
15 leukemia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001909
16 neoplasm of the gastrointestinal tract 58 30 Very rare (1%) Very rare (<4-1%)
HP:0007378
17 neoplasm of the lung 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100526
18 neoplasm of the thyroid gland 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100031
19 myositis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100614
20 demyelinating peripheral neuropathy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0007108
21 scleroderma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100324
22 prostate neoplasm 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100787
23 rheumatoid arthritis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001370
24 systemic lupus erythematosus 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002725
25 glomerulonephritis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000099
26 pure red cell aplasia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0012410
27 neoplasm of head and neck 58 30 Very rare (1%) Very rare (<4-1%)
HP:0012288
28 neoplasia of the pleura 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100527
29 ulcerative colitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100279
30 obstruction of the superior vena cava 58 30 Very rare (1%) Very rare (<4-1%)
HP:0031041
31 non-hodgkin lymphoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0012539
32 aplastic anemia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001915
33 imbalanced hemoglobin synthesis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0005560
34 autoimmunity 58 Occasional (29-5%)
35 decreased antibody level in blood 58 Occasional (29-5%)
36 neoplasm 58 Occasional (29-5%)
37 abnormality of the nervous system 58 Very rare (<4-1%)
38 acetylcholine receptor antibody positivity 58 Occasional (29-5%)
39 abnormal lymphocyte physiology 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

25 (show all 43)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.09 HRAS
2 Decreased viability GR00055-A-2 11.09 HRAS
3 Decreased viability GR00055-A-3 11.09 LCK
4 Decreased viability GR00221-A-1 11.09 AKT1 AKT3 HRAS LCK AKT2 KIT
5 Decreased viability GR00221-A-2 11.09 AKT1 AKT3 HRAS LCK TTN
6 Decreased viability GR00221-A-3 11.09 AKT1 AKT3 HRAS LCK AKT2
7 Decreased viability GR00221-A-4 11.09 AKT1 AKT3 TTN AKT2
8 Decreased viability GR00249-S 11.09 AKT1
9 Decreased viability GR00301-A 11.09 AKT3 LCK AKT2 KIT
10 Decreased viability GR00342-S-1 11.09 LCK TTN
11 Decreased viability GR00342-S-3 11.09 LCK TTN AKT2
12 Decreased viability GR00386-A-1 11.09 LCK
13 no effect GR00402-S-1 10.2 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
14 no effect GR00402-S-2 10.2 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.13 AKT2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.13 AKT3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.13 LCK
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.13 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.13 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.13 AKT2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.13 AKT3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.13 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.13 AIRE
24 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.13 LCK
25 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.13 AKT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.13 AIRE AKT2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.13 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.13 AKT2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.13 AKT3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.13 AKT1 AKT2 AKT3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.13 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.13 AKT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.13 AIRE
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.13 AKT1 AKT2 AKT3 KIT LCK
35 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.13 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-98 10.13 LCK
37 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.13 KIT
38 Decreased substrate adherent cell growth GR00193-A-1 10.06 AKT2 KIT
39 Decreased substrate adherent cell growth GR00193-A-2 10.06 AKT2 AKT3 KIT LCK
40 Decreased substrate adherent cell growth GR00193-A-3 10.06 AKT2 AKT3 LCK
41 Decreased substrate adherent cell growth GR00193-A-4 10.06 KIT LCK
42 Increased cell viability after pRB stimulation GR00230-A-1 9.65 AKT1 AKT2 AKT3 KIT LCK
43 Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation GR00363-A 8.85 HRAS

MGI Mouse Phenotypes related to Thymoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.37 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
2 homeostasis/metabolism MP:0005376 10.34 AIRE AKT1 AKT2 AKT3 CTLA4 DNTT
3 growth/size/body region MP:0005378 10.32 AIRE AKT1 AKT2 AKT3 CD5 GTF2I
4 immune system MP:0005387 10.24 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
5 endocrine/exocrine gland MP:0005379 10.23 AIRE AKT1 AKT2 AKT3 CTLA4 GTF2I
6 neoplasm MP:0002006 10.19 AIRE AKT1 AKT2 AKT3 HRAS IL2
7 cardiovascular system MP:0005385 10.18 AKT1 AKT3 CTLA4 GTF2I HRAS IL2
8 no phenotypic analysis MP:0003012 10.16 AIRE AKT2 CD5 GTF2I HRAS IL2
9 respiratory system MP:0005388 10.06 AIRE AKT1 AKT2 CTLA4 HRAS IL2
10 digestive/alimentary MP:0005381 10.03 AIRE CTLA4 HRAS IL2 KIT NKX2-1
11 reproductive system MP:0005389 10 AIRE AKT1 AKT2 AKT3 CD5 GTF2I
12 hematopoietic system MP:0005397 9.93 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
13 mortality/aging MP:0010768 9.8 AIRE AKT1 AKT2 AKT3 CTLA4 GTF2I
14 integument MP:0010771 9.36 AKT1 AKT2 CD5 CTLA4 EVPL HRAS

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 4 1374853-91-4 254741536
2 Tubulin Modulators Phase 4
3 Antimitotic Agents Phase 4
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Etoposide phosphate Phase 3 16760419
6
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
7
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
8
Pasireotide Approved Phase 2 396091-73-9 56841596 9941444
9
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
10
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
11
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
12
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
13
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605 16129706
14
Melphalan Approved Phase 2 148-82-3 4053 460612
15
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
16
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
17
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
18
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
19
Busulfan Approved, Investigational Phase 2 55-98-1 2478
20
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
21
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
22
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
23
Avelumab Approved, Investigational Phase 2 1537032-82-8
24
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
25
Ramucirumab Approved, Investigational Phase 2 947687-13-0
26
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
27
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
28
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
29
Cetuximab Approved Phase 2 205923-56-4
30
Nivolumab Approved Phase 1, Phase 2 946414-94-4
31
Nedaplatin Approved, Investigational Phase 2 95734-82-0
32
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
33
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
34
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
35
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
36
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
37
Sargramostim Approved, Investigational Phase 2 123774-72-1
38
Belinostat Approved, Investigational Phase 1, Phase 2 414864-00-9, 866323-14-0 53437714 6918638
39
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
40
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
41
Promethazine Approved, Investigational Phase 2 60-87-7 4927
42
Histamine Approved, Investigational Phase 2 51-45-6 774
43
Doxepin Approved, Investigational Phase 2 1668-19-5 667468 667477
44
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
45
Plicamycin Approved, Investigational, Withdrawn Phase 1, Phase 2 18378-89-7 163659 52945526
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 556-02-5, 60-18-4 1153 6057
48
Amrubicin Investigational Phase 2 110267-81-7 13502539 3035016
49
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
50
Lexatumumab Investigational Phase 2 845816-02-6

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery Recruiting NCT04554524 Phase 4 Chemotherapy+Pembrolizumab.
2 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Unknown status NCT02014805 Phase 3
3 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
4 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
5 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Unknown status NCT03466827 Phase 2 Selinexor
6 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Unknown status NCT02364076 Phase 2 Pembrolizumab;Epacadostat
7 Samsung Medical Center Unknown status NCT03219554 Phase 2 Palbociclib
8 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
9 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Completed NCT02307500 Phase 2 Regorafenib
10 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
11 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
12 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
13 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
14 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
15 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
16 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Completed NCT02049047 Phase 2 Everolimus
17 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
18 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
19 Radiofrequency Ablation of Pulmonary Malignancy Completed NCT00024076 Phase 2
20 A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Completed NCT02220855 Phase 2 BKM120
21 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
22 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
23 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
24 A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed NCT02420691 Phase 2 Ribociclib
25 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Completed NCT02607631 Phase 2 Pembrolizumab
26 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
27 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
28 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
29 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
30 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT04417660 Phase 2 M7824
31 A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT05104736 Phase 2 PT-112
32 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
33 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
34 Abscopal Effect and Safety of Recurrent and Refractory Advanced Thymic Epithelial Tumours Treated With Combined Therapy of Local Radiotherapy and Granulocyte-macrophage Colony-stimulating Factor Recruiting NCT05407649 Phase 2
35 A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI. Recruiting NCT04710628 Phase 2 Pembrolizumab;Lenvatinib 10 mg
36 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
37 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
38 A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma Recruiting NCT04469725 Phase 2 KN046
39 Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors Recruiting NCT04925947 Phase 2 KN046
40 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
41 An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Recruiting NCT04321330 Phase 2 Atezolizumab
42 A Phase II, Neo-adjuvant Pembrolizumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Pembrolizumab Consolidation Therapy in Locally Advanced Thymic Epithelial Tumor (TET) Recruiting NCT03858582 Phase 2 pembrolizumab
43 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
44 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
45 Hypofractionated Radiotherapy Combined With Concurrent Weekly Chemotherapy and Thymosin α1 in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-arm Phase II Study Active, not recruiting NCT03663764 Phase 2 Thymosin a1;concurrent chemoradiotherapy
46 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Active, not recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
47 Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
48 Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Not yet recruiting NCT04667793 Phase 2 Toripalimab;Chemotherapy
49 Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors Not yet recruiting NCT04517539 Phase 2 rhGM-CSF,Peginterferon alfa-b2,radiation
50 Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma) Terminated NCT00718809 Phase 2 saracatinib

Search NIH Clinical Center for Thymoma

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

Organs/tissues related to Thymoma:

FMA: Thymus
MalaCards : Thymus, Lung, Thyroid, Bone Marrow, T Cells, Prostate, B Cells

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 8869)
# Title Authors PMID Year
1
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. 62 5
19861435 2009
2
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. 62 5
18448188 2008
3
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
4
When a thymic carcinoma "becomes" a GIST. 5
23375402 2013
5
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 5
22357254 2012
6
Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. 5
21969494 2011
7
Large-scale analysis of KIT aberrations in Chinese patients with melanoma. 5
21325067 2011
8
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. 5
20970876 2011
9
Thymic tumors: relevant molecular data in the clinic. 5
20859122 2010
10
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. 5
20736294 2010
11
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. 5
19461405 2009
12
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. 5
17699867 2007
13
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. 5
17372901 2007
14
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. 5
15930355 2005
15
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. 5
15201427 2004
16
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. 5
12960119 2003
17
Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. 53 62
19876913 2010
18
Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. 53 62
19747927 2010
19
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. 53 62
19693092 2009
20
Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. 53 62
18635704 2009
21
AKT1 Gene Polymorphisms and Obstetric Complications in the Patients with Schizophrenia. 53 62
20046382 2009
22
Spiradenoma reminiscent of thymoma: report of a case and review of the literature. 53 62
18647207 2009
23
Early loss of mammalian target of rapamycin complex 1 (mTORC1) signalling and reduction in cell size during dominant-negative suppression of hepatic nuclear factor 1-alpha (HNF1A) function in INS-1 insulinoma cells. 53 62
18949455 2009
24
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. 53 62
18728167 2008
25
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells. 53 62
18509162 2008
26
Infrequent and low AIRE expression in thymoma: difference in AIRE expression among WHO subtypes does not correlate with association of MG. 53 62
18568643 2008
27
CRMP5 antibodies in patients with small-cell lung cancer or thymoma. 53 62
17657489 2008
28
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. 53 62
18567864 2008
29
Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity? 53 62
17928069 2007
30
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. 53 62
17590173 2007
31
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 53 62
17611497 2007
32
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. 53 62
17539937 2007
33
Is excitation-contraction coupling impaired in myasthenia gravis? 53 62
17307394 2007
34
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). 53 62
17334980 2007
35
Expression of p63 in thymomas and normal thymus. 53 62
17276940 2007
36
AKT1 and neurocognition in schizophrenia. 53 62
17464696 2007
37
[Thymus CT scan and thymoma associated antibodies in myasthenia gravis with thymoma]. 53 62
16995304 2006
38
Exogenous nitric oxide stimulates cell proliferation via activation of a mitogen-activated protein kinase pathway in ovine fetoplacental artery endothelial cells. 53 62
16251502 2006
39
[Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors]. 53 62
16608644 2006
40
Titin and ryanodine receptor antibodies in myasthenia gravis. 53 62
16637922 2006
41
Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. 53 62
16125946 2005
42
Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. 53 62
16120143 2005
43
Analysis of cell cycle regulator proteins in encapsulated thymomas. 53 62
16033820 2005
44
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. 53 62
15760917 2005
45
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]. 53 62
15634634 2004
46
Association of AKT1 with schizophrenia confirmed in a Japanese population. 53 62
15522255 2004
47
The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis. 53 62
15316806 2004
48
Expression of cyclins D1, D3 and p27 in thymic epithelial tumors. 53 62
17670226 2004
49
Hematopoietic progenitor cells as possible origins of epithelial thymoma in a human T lymphocyte virus type I pX gene transgenic rat model. 53 62
14688799 2004
50
Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. 53 62
14673901 2003

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KIT NM_000222.3(KIT):c.1468G>A (p.Glu490Lys) SNV Pathogenic
375903 rs1057519701 GRCh37: 4:55592144-55592144
GRCh38: 4:54725978-54725978
2 KIT NM_000222.3(KIT):c.1730_1738del (p.Pro577_Asp579del) DEL Pathogenic
375920 rs1131692239 GRCh37: 4:55593662-55593670
GRCh38: 4:54727496-54727504
3 KIT NM_000222.3(KIT):c.1657T>A (p.Tyr553Asn) SNV Pathogenic
375907 rs1057519704 GRCh37: 4:55593591-55593591
GRCh38: 4:54727425-54727425
4 KIT NM_000222.3(KIT):c.2460T>A (p.Asp820Glu) SNV Pathogenic
375929 rs1057519711 GRCh37: 4:55599334-55599334
GRCh38: 4:54733168-54733168
5 KIT NM_000222.3(KIT):c.1676TTG[1] (p.Val560del) MICROSAT Pathogenic
375913 rs121913685 GRCh37: 4:55593609-55593611
GRCh38: 4:54727443-54727445
6 KIT NM_000222.3(KIT):c.2089C>T (p.His697Tyr) SNV Pathogenic
375925 rs763308199 GRCh37: 4:55595599-55595599
GRCh38: 4:54729433-54729433
7 KIT NM_000222.3(KIT):c.1727T>C (p.Leu576Pro) SNV Pathogenic
375919 rs121913513 GRCh37: 4:55593661-55593661
GRCh38: 4:54727495-54727495
8 KIT NM_000222.3(KIT):c.1676T>C (p.Val559Ala) SNV Pathogenic
13865 rs121913517 GRCh37: 4:55593610-55593610
GRCh38: 4:54727444-54727444
9 KIT NM_000222.3(KIT):c.1669T>C (p.Trp557Arg) SNV Pathogenic
375909 rs121913235 GRCh37: 4:55593603-55593603
GRCh38: 4:54727437-54727437
10 HRAS, LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely Pathogenic
180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 RYR1 PTPRC KIT IL2 HRAS AKT3
2
Show member pathways
13.57 AKT1 AKT2 AKT3 CTLA4 HRAS LCK
3
Show member pathways
13.42 LCK KIT IL2 HRAS AKT3 AKT2
4
Show member pathways
13.42 LCK KIT IL2 HRAS GTF2I AKT3
5
Show member pathways
13.35 PTPRC KIT IL2 HRAS AKT3 AKT2
6
Show member pathways
13.03 LCK KIT IL2 HRAS AKT3 AKT2
7
Show member pathways
12.98 KIT IL2 HRAS AKT3 AKT2 AKT1
8
Show member pathways
12.93 RYR1 HRAS AKT3 AKT2 AKT1
9
Show member pathways
12.91 IL2 HRAS AKT3 AKT2 AKT1
10
Show member pathways
12.89 AKT1 AKT2 AKT3 HRAS IL2
11
Show member pathways
12.87 KIT HRAS AKT3 AKT2 AKT1
12
Show member pathways
12.85 PTPRC LCK HRAS CTLA4 AKT3 AKT2
13 12.83 LCK KIT HRAS AKT3 AKT2 AKT1
14
Show member pathways
12.75 KIT HRAS AKT3 AKT2 AKT1
15 12.73 KIT HRAS AKT3 AKT2 AKT1
16
Show member pathways
12.72 LCK KIT AKT3 AKT2 AKT1
17
Show member pathways
12.71 RYR1 HRAS AKT3 AKT2 AKT1
18
Show member pathways
12.63 LCK AKT3 AKT2 AKT1
19
Show member pathways
12.62 IL2 HRAS AKT3 AKT2 AKT1
20 12.59 PTPRC LCK KIT IL2 CTLA4
21
Show member pathways
12.57 NKX2-1 HRAS AKT3 AKT2 AKT1
22
Show member pathways
12.54 HRAS AKT3 AKT2 AKT1
23
Show member pathways
12.5 HRAS AKT3 AKT2 AKT1
24
Show member pathways
12.48 AKT1 AKT2 AKT3 CTLA4 LCK
25 12.45 HRAS AKT3 AKT2 AKT1
26
Show member pathways
12.45 HRAS AKT3 AKT2 AKT1
27
Show member pathways
12.45 HRAS AKT3 AKT2 AKT1
28
Show member pathways
12.45 KIT HRAS AKT3 AKT2 AKT1
29
Show member pathways
12.43 AKT1 AKT2 AKT3 HRAS IL2 KIT
30
Show member pathways
12.42 AKT1 AKT2 AKT3 HRAS IL2
31
Show member pathways
12.4 HRAS AKT3 AKT2 AKT1
32
Show member pathways
12.38 AKT1 AKT2 AKT3 HRAS
33
Show member pathways
12.37 HRAS AKT3 AKT2 AKT1
34
Show member pathways
12.37 HRAS AKT3 AKT2 AKT1
35
Show member pathways
12.36 HRAS AKT3 AKT2 AKT1
36
Show member pathways
12.36 LCK CTLA4 AKT3 AKT2 AKT1
37 12.34 HRAS AKT3 AKT2 AKT1
38
Show member pathways
12.31 HRAS AKT3 AKT2 AKT1
39
Show member pathways
12.31 PTPRC HRAS AKT3 AKT2 AKT1
40
Show member pathways
12.3 HRAS AKT3 AKT2 AKT1
41
Show member pathways
12.3 PTPRC LCK HRAS AKT3 AKT2 AKT1
42
Show member pathways
12.26 HRAS AKT3 AKT2 AKT1
43
Show member pathways
12.26 HRAS AKT3 AKT2 AKT1
44
Show member pathways
12.25 AKT1 AKT2 AKT3 HRAS
45
Show member pathways
12.24 HRAS AKT3 AKT2 AKT1
46 12.22 HRAS AKT3 AKT2 AKT1
47
Show member pathways
12.21 HRAS AKT3 AKT2 AKT1
48
Show member pathways
12.21 HRAS AKT3 AKT2 AKT1
49
Show member pathways
12.2 PTPRC LCK HRAS AKT3 AKT2 AKT1
50
Show member pathways
12.19 AKT1 AKT2 AKT3 IL2 LCK

GO Terms for Thymoma

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 10.01 TTN PTPRC LCK KIT
2 release of sequestered calcium ion into cytosol GO:0051209 9.85 RYR1 PTPRC LCK
3 T cell costimulation GO:0031295 9.8 LCK CD5 AKT1
4 phosphorylation GO:0016310 9.7 TTN LCK KIT AKT3 AKT2 AKT1
5 negative regulation of long-chain fatty acid import across plasma membrane GO:0010748 9.56 AKT1 AKT2
6 T cell receptor signaling pathway GO:0050852 9.56 PTPRC LCK HRAS CTLA4
7 T cell differentiation GO:0030217 9.23 PTPRC LCK KIT IL2

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.76 TTN RYR1 LCK KIT HRAS AKT3
2 kinase activity GO:0016301 9.5 TTN LCK KIT AKT3 AKT2 AKT1
3 protein kinase activity GO:0004672 9.23 TTN LCK KIT AKT3 AKT2 AKT1

Sources for Thymoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....